![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/psycheceutical-bioscience-inc-named-a-2023-top-10-biotech-startup-by-life-sciences-review-301796857.html
https://www.globenewswire.com/news-release/2023/03/29/2637071/0/en/Psycheceutical-Hosts-MAPS-Founder-and-Psychedelic-Industry-Leader-Rick-Doblin-at-Its-Drug-Development-Lab.html
https://www.globenewswire.com/news-release/2023/03/21/2631698/0/en/Psycheceutical-Bioscience-Inc-Announces-Observational-Research-Results-for-NeuroDirect-Ketamine-Topical-Cream-in-Treating-PTSD.html
https://www.globenewswire.com/news-release/2023/02/15/2609017/0/en/Psycheceutical-to-Conduct-the-First-Ever-Phase-I-and-II-Clinical-Trials-of-a-Novel-Ketamine-Topical-Cream-to-Treat-PTSD.html
https://www.globenewswire.com/news-release/2023/02/02/2600676/0/en/Psycheceutical-Announces-Completion-of-Pre-IND-Meeting-with-FDA-for-Topical-Ketamine-Drug-to-Treat-PTSD.html
https://www.globenewswire.com/news-release/2023/01/26/2596339/0/en/Psycheceutical-Bioscience-Provisional-Patent-Application-for-Novel-Ketamine-Topical-for-the-Treatment-of-PTSD.html
https://www.globenewswire.com/news-release/2023/01/10/2586577/0/en/Psycheceutical-Announces-Julian-Bailes-M-D-as-Board-Member-and-Chief-Medical-Officer.html
https://www.globenewswire.com//news-release/2022/11/29/2564323/0/en/Dr-Aric-Logsdon-Joins-Psycheceutical-Bioscience-Inc-as-Company-s-Scientific-Director.html
https://www.globenewswire.com/news-release/2022/10/04/2528003/0/en/Psycheceutical-Bioscience-Inc-s-Zappy-Zapolin-Added-to-The-Benzinga-Psychedelics-Advisory-Council.html
https://www.globenewswire.com/news-release/2022/08/16/2499318/0/en/Psycheceutical-Bioscience-Inc-Enters-into-Exclusive-Option-to-Acquire-Vici-Health-Sciences.html